January 28, 2021 07:22 AM ESTUpdated 08:24 AM

Covid-19 roundup: Controversy around colchicine percolates after study failure; AstraZeneca's meeting with EU was 'constructive,' but didn't solve much

Amber Tong

Senior Editor

Nicole DeFeudis

Editor

A group of researchers at the Montreal Heart Institute has spelled out what they had called positive results suggesting that colchicine, an inexpensive oral anti …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Covid-19 roundup: Controversy around colchicine percolates after study failure; AstraZeneca's meeting with EU was 'constructive,' but didn't solve much

Amber Tong

Senior Editor

Nicole DeFeudis

Editor

Sign up to read this article for free.

Among pharma CEOs, the IRA now and the IRA later get very different reactions

Bristol Myers restarts radiopharmaceutical Phase 3 trial, but delays readout by one year

Andrew Left, short seller who campaigned against Valeant, is accused of fraud by SEC

Updated: With cost-cutting underway, Bristol Myers raises guidance, touts Phase 3 win and scraps another

European drug regulator rejects Alzheimer's drug Leqembi, citing safety concerns

Critical Junctures in Gene Therapy Clinical Material Manufacturing: Where Do I Start? And Will It Work?

Covid-19 roundup: Con­tro­ver­sy around colchicine per­co­lates af­ter study fail­ure; As­traZeneca's meet­ing with EU was 'con­struc­tive,' but did­n't solve much

Senior Editor

Editor

Sign up to read this article for free.

Covid-19 roundup: Controversy around colchicine percolates after study failure; AstraZeneca's meeting with EU was 'constructive,' but didn't solve much